Sunday, May 9, 2021
Aditxt (NASDAQ: ADTX) Secures CLIA Certification for AditxtScore Laboratory Operations in Richmond, VA, and Plans to Launch AditxtScore™ for COVID-19 as a Lab Developed Test (LDT)
Upcoming Vaccines Increase the Need for Ongoing Monitoring of Presence and Durability of Immunity Mountain View, CA , Nov. 19,...
Read more
3 Healthcare Microcaps Rated “Strong Buy” By Top-Ranked Analysts
Not all analysts and their respective opinions are created equal. Reputation and track record can be defining features that elevate...
Read more
Aditx Therapeutics, Inc. (NASDAQ: ADTX) Provides Business Update and Files Third Quarter 2020 10-Q
Mountain View, CA, Nov. 13, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life...
Read more
Physician and Media Personality Dr. Drew Pinsky, Dr. Drew, Joins Aditx Therapeutics (NASDAQ: ADTX) as Senior Advisor to AditxtScore™ for Scoring the Immune System
Loma Linda, CA, Sept. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX),...
Read more
The Two Biggest Names in Telemedicine Plan $18.5 Billion Merger
Telemedicine services providers, Teledoc Health, Inc. (NYSE: TDOC) and Livongo Health, Inc. (NASDAQ: LVGO), have agreed to an $18.5 billion...
Read more
Multiple Companies Approach the Finish Line in Race for a Coronavirus Vaccine
The coronavirus pandemic continues to rage through much of the globe – but relief may be in sight. Buoyed by...
Read more
Translate Bio, Inc. (NASDAQ: TBIO) Surges 42% After Expanding Collaboration with Sanofi to Develop mRNA Vaccines for Infectious Diseases
Translate Bio, Inc. (NASDAQ: TBIO) is a clinical-stage mRNA therapeutics company with a focus on development of treatments for diseases...
Read more
Edesa Biotech, Inc. (NASDAQ: EDSA) Surges 100% After Receiving Approval to Begin COVID-19 Phase 2/3 Clinical Trials from Health Canada
Edesa Biotech, Inc. (NASDAQ: EDSA) is a clinical-stage biopharmaceutical company that specializes in treatments for dermatological and gastrointestinal ailments. Shares...
Read more
Immuron Limited (NASDAQ: IMRN) (ASX: IMC) Skyrockets 727% After NMRC Requests Meeting with FDA Regarding Phase 2 Clinical Trials For New Treatment of Diarrheal Infections
Immuron Limited (NASDAQ: IMRN) (ASX: IMC) is an Australia-based biopharmaceutical company with a focus on the research and development of...
Read more
Demand for Telehealth Services Rises as Coronavirus Spreads
As the coronavirus pandemic continues to spread and forcing people to remain in quarantine, remote alternatives to necessary services are...
Read more
